Association of homeobox B13 (HOXB13) gene variants with prostate cancer risk in an Iranian population

Raheleh Roudi1, Hosein Nemati2, Mahsa Rastegar Moghadam3, Mehdi Sotoudeh4, Behzad Narouie5 Azadeh Shojaei*3

Received: 19 Dec 2017 Published: 7 Oct 2018

Abstract

Background: Prostate cancer is a complex condition in which both genetic and environmental factors concomitantly contribute to the tumor initiation and progression. Recently, HOXB13 has been proposed as a susceptibility gene for prostate cancer.

Objective: The present study was conducted to determine the existence of potential variations in HOXB13 gene in Iranian men with prostate cancer (PCa) compared to benign prostatic hyperplasia (BPH) cases.

Methods: HOXB13 genetic status was screened in 51 samples, including 21 blood and tissue of PCa cases, and compared to 30 cases affected by BPH using PCR/sequencing. Then, the existence of potential association was investigated between genomic DNA alterations in blood and tissue PCa specimens.

Results: Analysis of BPH tissues showed single nucleotide variations c.366C > T (rs) or c.513T > C (rs9900627) in exon 1, but not in exon 2. Evaluation of PCa tissues revealed 2 cases with both synonymous c.366C > T and c.513T > C variants and 2 cases with the synonymous c.366C > T variant in exon 1. The variants c.366C > T and c.513T > C, simultaneously or separately, were found in blood samples of PCa patients. The novel variant c.127A > G in exon 2 was detected in 1 PCa blood sample. Our analysis indicated a significant reciprocal correlation between HOXB13 mutation in the tissue and blood samples of PCa cases (p= 0.02).

Conclusion: The variants in exon 2 of HOXB13 may influence the risk of prostate cancer. Also, evaluation of HOXB13 mutation may be considered as a novel marker for screening PCa. Further investigations are warranted to evaluate the clinical significance of HOXB13 in Iranian population.

Keywords: Prostate cancer, HOXB13, Benign prostatic hyperplasia, Variant, Iran

Conflict of Interest: None declared

Funding: None declared

*This work has been published under CC BY-NC-SA 1.0 license.


Introduction

Prostate cancer (PCa) is considered the second most common malignancy after lung cancer in men and the sixth leading cause of cancer-related death worldwide (1). The 5-year survival rate in benign prostatic hyperplasia (BPH) is about 100%, but the occurrence of metastasis to distant organs would decrease to 31% in PCa (2).

Depending on the tumor stage, therapeutic options can be different ranging from radiation therapy to radical prostatectomy for the benign localized tumor and anti-androgen therapy for metastatic types. It has been demonstrated that in the case of hormonal therapy, 20% to 30% of tumors will develop resistance and become more
HOXB13 gene variants in prostate cancer

aggressive; they are known as castration-resistant prostate cancer (CRPC) (3).

HOXB13 is one of the members of HOX gene superfamily and possesses a broad range of expression patterns from low levels in colon and rectum to high levels in the normal prostate gland and prostate cancer (4, 5). HOX gene superfamily encodes homeoproteins as transcription factors having an important regulatory role in axial-regional differentiation during embryonic development, cell proliferation, and development of sex organs (6). After screening 17q21-22 region as a susceptibility locus for prostate cancer performed by Ewing et al. at the beginning of 2012, HOXB13 was introduced as a high-risk gene for PCa susceptibility (7). The G84E (rs138213197) is a rare and recurrent mutation on a highly conserved domain of HOXB13 protein that was observed in germline DNA of European descent men with prostate cancer (8). Subsequent studies showed a higher frequency of HOXB13 G84E mutation in positive history and early-onset of PCa compared to healthy individuals (9, 10). A previous project demonstrated HOXB13 G135E as a novel mutation conferring the risk of PCa in Chinese men (11). It has been reported that overexpression of HOXB13 is correlated with advanced pathologic stage of the disease, Gleason's score, the involvement of lymph node, and shorter survival rate (12). It has also been shown that HOXB13 can be a potential candidate for clinical application by itself, or in combination with other markers (13).

The accumulating evidence indicates the pivotal role of mutation or dysregulation of HOXB13 gene in PCa, but there is no convincing data about this gene. Additionally, there is no data about the role of HOXB13 in development of PCa in Iranian men (14). The present study aims at exploring the presence of HOXB13 mutations in patients with PCa compared to BPH patients.

Methods

Study population and clinical sample collection

A total of 56 samples (21 PCa cases and 35 BPH cases) were recruited from a major referral urology-nephrology center in Iran (Labbafinezhad Hospital) from July 2015 to April 2016. Written informed consent was obtained from all patients. Tissue specimens were obtained by radical prostatectomy or transurethral resection (TURP) and were immediately snap-frozen in liquid nitrogen and stored at -80°C until use. For each PCa patient, venous blood samples were collected in ethylene diamine tetra acetic acid (EDTA)-containing tubes and stored at -80°C for DNA extraction. The specimens were obtained before any treatment modalities, including radiotherapy and chemotherapy. Clinicopathologic data of enrolled patients, including age, history of PCa in the family, smoking, serum prostate-specific antigen (PSA) level, and Gleason score were collected and recorded. This study was approved by the Ethical Committee of Iran University of Medical Sciences.

DNA extraction of frozen tissues and blood samples

To analyze HOXB13 gene in PCa and BPH tissues and patients' blood, genomic DNA was extracted using the YT9030 kit (Yekatajihiz, Tehran, Iran). TG1 buffer and Proteinase K were added to tissues and incubated at 60°C overnight. After finishing the tissue lysis, TG2 buffer was added and incubated at 70°C for 10 minutes. Then, ethanol was added and the mixture was transferred to the column and after 2 times of washing, the DNA was precipitated. Genomic DNA extraction of blood samples was performed using the YT9040 kit (Yekatajihiz, Tehran, Iran), according to manufacturer's instructions. Briefly, BG buffer and Proteinase K were added to the blood sample and incubated at 60°C for 15 minutes. Then, ethanol was added and the mixture was transferred to the column and after 2 times of washing, DNA was precipitated. Quality and quantity of DNA were evaluated using gel electrophoresis and Nanodrop, respectively.

Genotyping of HOXB13 gene and sequence analysis

Two exons of HOXB13 gene (NM_006361.5) were screened for genetic variations by PCR. Each PCR reaction with 25 μL reaction mixture contained 2.4 μL of 2× reaction buffer, 2 μL of genomic DNA templates, 0.1 μL of Taq DNA polymerase (5 U/μL), 1 μL of each primer, 1.5 μL of MgCl₂ (50Mmol), and 0.5 μM of dNTP (10Mm). After initial denaturation at 94°C for 3 min, 32 PCR cycles were performed using Biorad thermocycler (Bio-Rad Laboratories, Hercules, CA, USA); each cycle for exon 1 included denaturation at 94°C in 30 s, annealing at 64°C in 30 s, extension at 72°C for 1 min, and final extension at 72°C in 10 min, respectively. All cycling steps of exon 2 are the same as exon 1 except annealing at 62°C. PCR products were subjected to electrophoresis on agarose gel (1.5%), followed by staining with green viewer (3.5 μg/mL) to verify the anticipated length of amplified fragments. Direct sequencing was used with primers (Table 1). Sequencing was done by MACROGEN Company in South Korea using a classic Sanger method with ABI.

Statistical analysis

The analysis of sequencing data was performed by mutation surveyor software (SoftGenetics, Pennsylvania, USA). All data were analyzed using SPSS software version 20 (SPSS, Chicago, IL, USA). The correlation between HOXB13 mutation and clinicopathological

Table 1. The sequence of HOXB13 primers for exon 1 and exon 2

<table>
<thead>
<tr>
<th>Primer</th>
<th>Forward</th>
<th>Reverse</th>
<th>Product size (bp)</th>
<th>Tm (°C)</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXON 1</td>
<td>CGAGCTGGGAGCGGTATTA</td>
<td>AGCTCAAGTCTCCCCCTCCTC</td>
<td>769</td>
<td>64</td>
</tr>
<tr>
<td>EXON 2</td>
<td>GCCCTGATGGTGACGCTGTGT</td>
<td>TCCGGTCTCCCTGCACATCT</td>
<td>522</td>
<td>62</td>
</tr>
</tbody>
</table>
parameters were evaluated using Pearson’s χ² and Fisher's exact test. A p-value of ≤ 0.05 was considered statistically significant.

**Results**

**Clinicopathological information and HOXB13 variations in BPH cases**

The mean age of BPH cases was 71.3 ± 1.6 years (range 54 – 89 years). Mean of PSA level in BPH samples was 3.96 ± 0.69 (range: 1 - 15). In the analysis of BPH tissues, six (17.64%) of 34 cases had single nucleotide variation in exon 1, whereas no nucleotide change was found in exon 2. Among six, three samples were c.366C > T (rs8556) and other three had the c.513T > C (rs9900627) (Table 2).

**Clinicopathological information and HOXB13 variations in PCa cases**

The mean age of PCa patients was 63.67±1.9 years (50–83 years). The mean of PSA level in PCa cases was 17.16±4.28 (range: 5–83). Eight (38%) and 4 (19%) of PCa patients had Gleason score 6 and 7, respectively, whereas Gleason scores 8 and higher was found in 5 (24%) of PCa samples.

Investigation of PCa tissue samples demonstrated that 4 (19.04%) cases had single nucleotide variation in exon 1. Among them, 2 cases had both synonymous c.366C > T (rs8556) and c.513T > C (rs9900627) variants, and 2 cases displayed the synonymous c.366C > T variant (Table 3). Evaluation of PCa blood samples revealed that 9 (42.85%) of cases had variant in exon 1, whereas only 1 case showed variant in exon 2. The variants c.366C > T and c.513T > C were simultaneously found in 2 patients, c.366C > T was detected in 2 samples, and c.513T > C was seen in 4 PCa patients (Table 4). In exon 2, the novel variant c.127A > G was detected in 1 PCa blood sample (Fig. 1). Exploration of the association between HOXB13 mutation in the tissue and blood in PCa cases showed a significant reciprocal correlation (p= 0.02, Fig. 2).

<table>
<thead>
<tr>
<th>PATIENT CODE</th>
<th>LOCATION</th>
<th>CDNA ALTERATION</th>
<th>RS NUMBER</th>
<th>CLASSIFICATION</th>
<th>VARIANT TYPE</th>
</tr>
</thead>
<tbody>
<tr>
<td>A-05</td>
<td>Exon 1</td>
<td>c.366C &gt; T</td>
<td>rs8556</td>
<td>Heterozygote</td>
<td>Synonymous</td>
</tr>
<tr>
<td>C-04</td>
<td>Exon 1</td>
<td>c.366C &gt; T</td>
<td>rs8556</td>
<td>Heterozygote</td>
<td>Synonymous</td>
</tr>
<tr>
<td>D-04</td>
<td>Exon 1</td>
<td>c.513T &gt; C</td>
<td>rs9900627</td>
<td>Heterozygote</td>
<td>Synonymous</td>
</tr>
<tr>
<td>D-11</td>
<td>Exon 1</td>
<td>c.366C &gt; T</td>
<td>rs8556</td>
<td>Heterozygote</td>
<td>Synonymous</td>
</tr>
<tr>
<td>H-04</td>
<td>Exon 1</td>
<td>c.513T &gt; C</td>
<td>rs9900627</td>
<td>Heterozygote</td>
<td>Synonymous</td>
</tr>
<tr>
<td>C-07</td>
<td>Exon 1</td>
<td>c.513T &gt; C</td>
<td>rs9900627</td>
<td>Heterozygote</td>
<td>Synonymous</td>
</tr>
</tbody>
</table>

Table 3. Somatic HOXB13 variants detected in prostate cancer patients

<table>
<thead>
<tr>
<th>PATIENT CODE</th>
<th>LOCATION</th>
<th>CDNA ALTERATION</th>
<th>RS NUMBER</th>
<th>CLASSIFICATION</th>
<th>VARIANT TYPE</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Exon 1</td>
<td>c.366C&gt;T</td>
<td>rs8556</td>
<td>Heterozygote</td>
<td>Synonymous</td>
</tr>
<tr>
<td>2</td>
<td>Exon 1</td>
<td>c.513T&gt;C</td>
<td>rs8556</td>
<td>Heterozygote</td>
<td>Synonymous</td>
</tr>
<tr>
<td>4</td>
<td>Exon 1</td>
<td>c.366C&gt;T</td>
<td>rs8556</td>
<td>Heterozygote</td>
<td>Synonymous</td>
</tr>
<tr>
<td>15</td>
<td>Exon 1</td>
<td>c.366C&gt;T c.513T&gt;C</td>
<td>rs8556</td>
<td>Heterozygote</td>
<td>Synonymous</td>
</tr>
</tbody>
</table>

Table 4. Germline variants detected in prostate cancer patients

<table>
<thead>
<tr>
<th>Patient Code</th>
<th>Location</th>
<th>cDNA Alteration</th>
<th>rs Number</th>
<th>Classification</th>
<th>Variant Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Exon 1</td>
<td>c.366C&gt;T</td>
<td>rs8556</td>
<td>Heterozygote</td>
<td>Synonymous</td>
</tr>
<tr>
<td>4</td>
<td>Exon 1</td>
<td>c.513T&gt;C</td>
<td>rs8556</td>
<td>Heterozygote</td>
<td>Synonymous</td>
</tr>
<tr>
<td>5</td>
<td>Exon 1</td>
<td>c.513T&gt;C</td>
<td>rs9900627</td>
<td>Heterozygote</td>
<td>Synonymous</td>
</tr>
<tr>
<td>9</td>
<td>Exon 1</td>
<td>c.513T&gt;C</td>
<td>rs9900627</td>
<td>Heterozygote</td>
<td>Synonymous</td>
</tr>
<tr>
<td>11</td>
<td>Exon 1</td>
<td>c.513T&gt;C</td>
<td>rs9900627</td>
<td>Heterozygote</td>
<td>Synonymous</td>
</tr>
<tr>
<td>12</td>
<td>Exon 2</td>
<td>c.728A&gt;G</td>
<td>rs9900627</td>
<td>Heterozygote</td>
<td>New Variant</td>
</tr>
<tr>
<td>13</td>
<td>Exon 1</td>
<td>c.513T&gt;C</td>
<td>rs9900627</td>
<td>Heterozygote</td>
<td>Synonymous</td>
</tr>
<tr>
<td>15</td>
<td>Exon 1</td>
<td>c.366C&gt;T</td>
<td>rs8556</td>
<td>Heterozygote</td>
<td>Synonymous</td>
</tr>
<tr>
<td>19</td>
<td>Exon 1</td>
<td>c.366C&gt;T c.513T&gt;C</td>
<td>rs8556</td>
<td>Heterozygote</td>
<td>Synonymous</td>
</tr>
</tbody>
</table>
The association between HOXB13 mutations with clinicopathological data

The relationship between HOXB13 mutation and clinicopathologic parameters in PCa and BPH cases was explored using chi-square test. Our analysis showed a significant association between no mutation in HOXB13 gene and low PSA level (< 4 ng/mL), (chi-square (2, N= 51) = 11.05, p= 0.05) (Table 5). The HOXB13 gene mutation showed a marginal trend between PCa compared to BPH cases, (chi-square (2, N= 55) = 5.1, p= 0.08). No significant association was found between HOXB13 gene mutation and family history and smoking (chi-square (2, N= 55) = 11.1, p= 0.18, and chi-square (2, N= 55) = 7, p=0.89, respectively).

Discussion

Twin studies have shown that there is a strong genetic background in the predisposing of PCa compared to other common cancers, including breast, ovarian, and colorectal cancers (15). Therefore, a large body of studies has demonstrated a correlation between genetic variations, including single nucleotide polymorphisms (SNPs), and risk of PCa (16). Homeobox B13 (HOXB13) gene is implicated in the normal formation of the urogenital tract and its dysregulation was reported as a strong candidate gene for developing PCa (12, 17, 18).

In Iran, prostate cancer ranks the third most common fatal malignant tumor, and to the best of our knowledge there is no data regarding the analysis of HOXB13 in Iranian men. Thus, in the present study, we explored the variant(s) in PCa patient tissues compared to BPH cases (19-22). In addition, the potential variant(s) was investigated in the blood samples of PCa. All PCa tissues with mutation in HOXB13 gene (four cases) and the majority of PCa blood samples (6 out of 9 cases) had c.366C > T variant (rs8556). Surprisingly, our analysis revealed a novel variant c.728A>G in exon 2 of HOXB13 in one case of PCa blood sample. In the BPH tissues with mutation, our findings indicated that there are only c.366C > T (rs8556) or c.513T > C (rs9900627) variants. The correlation between HOXB13 G84E mutation (rs138213197) and prostate cancer risk has been investigated in European populations (23, 24). The incidence of this mutation was reported from 1.06% in northern European populations to 1.5% in the UK, but we did not detect such mutation in Iranian men. In a study conducted by Hamid et al., evaluation of HOXB13 in prostate cancer cell lines revealed that HOXB13 has a key role in cell cycle regulation (25). Their analysis, conducted on Turkish population, also showed increased expression of HOXB13 in prostate cancer compared to non-malignant prostate tissues (25). No data on HOXB13 are available from Iraq and Pakistan for comparison.

Our findings also showed a significant correlation between HOXB13 mutation in the tissue and blood samples of PCa patients. Varinot et al. demonstrated more than 90% sensitivity for HOXB13 gene in metastatic cases of PCa (26). A previous study also indicated that HOXB13 gene had the sensitivity and specificity of 100% and 94% for PCa, respectively (27). It can be concluded that HOXB13 may be considered as a potential marker for screening and identification of PCa.

Table 5. Association between patient characteristics and HOXB13 gene mutation (The values shown in bold, are statistically significant)

<table>
<thead>
<tr>
<th>Patient characteristics</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean of age</td>
<td>0.75</td>
</tr>
<tr>
<td>&lt; 68 vs &gt; 68</td>
<td></td>
</tr>
<tr>
<td>PCa vs BPH</td>
<td>0.08</td>
</tr>
<tr>
<td>PSA level</td>
<td></td>
</tr>
<tr>
<td>&lt;4</td>
<td>0.05</td>
</tr>
<tr>
<td>4-10</td>
<td></td>
</tr>
<tr>
<td>&gt;10</td>
<td></td>
</tr>
<tr>
<td>Family history</td>
<td>0.18</td>
</tr>
<tr>
<td>Yes vs no</td>
<td></td>
</tr>
<tr>
<td>Smoking inhalation</td>
<td>0.89</td>
</tr>
<tr>
<td>Yes vs no</td>
<td></td>
</tr>
</tbody>
</table>

![Fig. 1. The c.728A>G variant in exon 2 of blood of prostate cancer (Code=12)](http://mjiri.iums.ac.ir)

![Fig. 2. The correlation between HOXB13 gene mutation in tissue and blood specimens of prostate cancer patients](http://mjiri.iums.ac.ir)
Screening HOXB13 mutations in a large population of Iranian men is suggested. Analysis of HOXB13 expression at the levels of both gene and protein could shed light on cellular and molecular aspects of the function of this gene in prostate cancer tumorigenesis. Also, evaluation of HOXB13 along with other prostate cancer susceptibility genes, including BRCA1, BRCA2, and androgen receptor (AR), is warranted.

**Conclusion**

Variations were found in the BPH samples in exon 1, but not in exon 2. The variants in exon 2 of HOXB13 may influence prostate cancer susceptibility. Furthermore, evaluation of HOXB13 mutation may be considered as a novel marker for screening PCa. Further investigations are warranted to evaluate the clinical significance of HOXB13 in Iranian population.

**Acknowledgments**

None.

**Human participants**

All procedures were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 (5). Informed consent was obtained from all patients.

**Conflict of Interests**

The authors declare that they have no competing interests.

**References**
